FDA accepts Onward BCI into advisory program March 11, 2024 Onward Medical announced today that the FDA accepted it into its new Total Product Lifecycle Advisory Program (TAP) — a move that could boost the development of Onward’s BCI technology. Read More »
FDA clears pulsed field ablation electrode tech from Pulse Biosciences March 11, 2024 Pulse Biosciences (Nasdaq:PLSE) announced that the FDA granted 510(k) clearance for its CellFX nsPFA percutaneous electrode system. Read More »
FDA panel backs Lumicell’s agent for breast cancer imaging tool March 11, 2024 One panelist who voted yes said the “incremental benefits outweigh the small risks of anaphylaxis.” Read More »